Crizotinib Approval Expanded for Advanced Lung Cancer

The Food and Drug Administration (FDA) has expanded the approved uses of the targeted therapy crizotinib (Xalkori®) for patients with non-small cell lung cancer (NSCLC).

The new approval is for the treatment of patients with advanced NSCLC whose tumors have alterations—known as rearrangements—in the ROS1 gene. Crizotinib was originally approved for patients with advanced NSCLC whose tumors have similar alterations in the ALK gene.

from Cancer via ola Kala on Inoreader http://ift.tt/1o7TXJC
via IFTTT